INTRODUCTION
Neurotrophic factors have garnered a poor reputation in the management of ALS because of well publicized, failed clinical trials (ALS CNTF Study Group 1996; Cedarbaum et al., 1998) . Given the economics of large-scale controlled clinical trials, better models are needed to provide more predictive efficacy testing of the numerous rational therapies, including neurotrophic factors. Several neurotrophic factors have seemed particularly promising for use in motor neuron diseases because they promote motor neuron survival in the developing nervous system. Insulinlike growth factor-I (IGF-I) (Neff et al., 1993) , glial cell-line derived neurotrophic factor (GDNF) (Henderson et al., 1994; Oppenheim et al., 1995) , brain-derived neurotrophic factor (BDNF) (Henderson et al., 1993; Oppenheim et al., 1992; Yan et al., 1992) , neurotrophic factor-4/5 (NT-4/5) (Henderson et al., 1993) , ciliary neurotrophic factor (CNTF) (Arakawa et al., 1990; Oppenheim et al., 1991) , and leukemia inhibitory factor (LIF) (Martinou et al., 1992) increase embryonic motor neuron survival in culture and reduce naturally occurring embryonic motor neuron death in vivo.
Some neurotrophic factors alter neuronal sensitivity to various insults, such as serum deprivation, oxygenglucose deprivation, acute glutamate toxicity, and oxidative injury (Skaper et al., 1998; Cheng et al., 1994 Cheng et al., , 1995 Jackson et al., 1990; Koh et al., 1995; Mattson et al., 1993; Skaper et al., 1993) . While neurotrophic factors appear neuroprotective in some paradigms, in others, they can actually potentiate toxicity (Koh et al., 1995) . Experiments on immature neurons have obvious limited applicability to acquired human disease in late life because the effects of neurotrophic factors may be
